Administration of the nitric oxide synthase inhibitor NG-methyl-l-arginine hydrochloride (546C88) by intravenous infusion for up to 72 hours can promote the resolution of shock in patients with severe sepsis: Results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002)*
Jan Bakker(Pontificia Universidad Católica de Chile), Jukka Takala(University of Bern), Steven H. Grossman(GlaxoSmithKline (Netherlands)), Jill Donaldson(GlaxoSmithKline (Netherlands)), Jan Andersson(National Pedagogic University), Angela McLuckie(Guy's Hospital), Laurent Holzapfel(Servier (France)), David I. Watson(Townsville Hospital), Robert F. Grover(University of Colorado Boulder), Robert F. Lodato
Cited by 196
Related Papers
The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure
|Intensive Care Medicine|1996|11.7k
Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units
|Critical Care Medicine|1998|3.5k
Consensus on circulatory shock and hemodynamic monitoring. Task force of the European Society of Intensive Care Medicine
|Intensive Care Medicine|2014|1.8k
Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: Effect on survival in patients with septic shock*
|Critical Care Medicine|2004|921
Serial blood lactate levels can predict the development of multiple organ failure following septic shock
|The American Journal of Surgery|1996|857